Systematic Review with Network Meta-Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients

Table 2

Summary matrix showing all pairwise comparisons for treatment-emergent adverse events.

AML5	0.82 (0.46, 1.47)	0.84 (0.25, 2.84)	1.39 (0.43, 4.6)	0.51 (0.14, 1.65)	0.26 (0.09, 0.69)	0.89 (0.25, 3.04)
1.23 (0.68, 2.16)	AZL20_AML5	1.03 (0.26, 3.95)	1.7 (0.46, 6.36)	0.62 (0.15, 2.34)	0.32 (0.09, 0.99)	1.08 (0.27, 4.23)
1.19 (0.35, 4.04)	0.97 (0.25, 3.78)	CAN8_AML5	1.65 (0.3, 8.99)	0.59 (0.1, 3.28)	0.31 (0.06, 1.49)	1.05 (0.18, 5.95)
0.72 (0.22, 2.31)	0.59 (0.16, 2.16)	0.61 (0.11, 3.29)	FIM60_AML5	0.36 (0.06, 1.93)	0.19 (0.04, 0.87)	0.64 (0.19, 2.02)
1.98 (0.6, 7.27)	1.62 (0.43, 6.76)	1.69 (0.3, 9.87)	2.76 (0.52, 16.13)	LOS50_AML5	0.51 (0.1, 2.63)	1.76 (0.3, 10.61)
3.84 (1.45, 11.71)	3.15 (1.01, 10.97)	3.28 (0.67, 16.74)	5.38 (1.15, 27.26)	1.95 (0.38, 9.9)	TEL40_AML25	3.43 (0.68, 17.85)
1.13 (0.33, 3.99)	0.92 (0.24, 3.71)	0.95 (0.17, 5.49)	1.57 (0.5, 5.27)	0.57 (0.09, 3.29)	0.29 (0.06, 1.46)	PBO

Abbreviations: AML, amlodipine; AZL, azilsartan; CAN, candesartan; FIM, fimasartan; TEL, telmisartan; LOS, losartan; PBO, placebo; CI, confidence intervals.